TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05675319
Drug: pomalidomide/bortezomib/dexamethasone (PVD)
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: carfilzomib/daratumumab/dexamethasone (KDD)
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: Autologous Stem Cells
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Stem Cell Transplantation
Study: NCT05675319
Drug: daratumumab/pomalidomide/dexamethasone (DPD)
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: isatuximab/carfilzomib/dexamethasone (Isa-KD)
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: selinexor/bortezomib/dexamethasone (SVD)
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05549167
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
Study: NCT05815901
Drug: Febuxostat 40 mg
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40 mg tablet
Study: NCT05815901
Drug: Febuxostat 80 mg
Normalized name: febuxostat 80 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 80 mg tablet
Study: NCT05815901
Drug: Epaminurad 6 mg placebo
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05815901
Drug: Epaminurad 9 mg placebo
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05815901
Drug: Febuxostat 40 mg placebo
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo tablet
Study: NCT05815901
Drug: Febuxostat 80 mg placebo
Normalized name: febuxostat 80 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo tablet
Study: NCT05874778
Drug: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
Normalized name: (2R,4'R,8'R)-α-tocopherol
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
Study: NCT04340908
Drug: Dapagliflozin 10 MG
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg tablet, oral, once daily, 1-year treatment, postoperation
Study: NCT05376904
Drug: ropivacaine HCl.
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine HCl.
Study: NCT04799847
Drug: Catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
Study: NCT00022893
Drug: Iodine-131 Anti-B1 Antibody
Normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05553093
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirzepatide ih qw
Study: NCT05553093
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 IU ih qd
Study: NCT04850235
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
Study: NCT04839055
Drug: Coenzyme A Combined With Abiraterone
DrugBank: Coenzyme A (DB01992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone 4 pieces per day. Coenzyme A 200U
Study: NCT04839055
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone
Study: NCT06396416
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Study: NCT05701241
Drug: Somatostatin analog
Normalized name: Somatostatin analog
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analog treatment every 4 weeks
Study: NCT04297618
Drug: Xiidra
Normalized name: Xiidra
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xiidra (lifitegrast 5% ophthalmic solution)
Study: NCT06376981
Drug: Hyaluronic acid injection
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An injection of 2 ml of Acid hyaluronic
Study: NCT06625450
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib alone will be continued at a dose of 11 mg once a day
Study: NCT06625450
Drug: Tofacitinib plus mesalamine
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both tofacitinib 11 mg once a day and mesalamine will be continued
Study: NCT05578430
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg by intravenous infusions every 3 weeks
Study: NCT04161599
Drug: Cefuroxime (750mg) I.V
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extra dosage
Study: NCT04161599
Drug: Cefuroxime 750mg oral
Normalized name: cefuroxime 750 MG
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prophylaxis
Study: NCT04161599
Drug: Metronidazole 250 MG Oral Tablet [Flagyl]
Normalized name: metronidazole 250 MG Oral Tablet [Flagyl]
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prophylaxis
Study: NCT04161599
Drug: Metronidazole 1 g Intravenous
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV prophylaxis
Study: NCT04161599
Drug: Cefuroxime 1,5 g Intravenous
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV prophylaxis
Study: NCT04716413
Drug: Dsuvia
Normalized name: Dsuvia
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
Study: NCT05048368
Drug: Larotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 350 mg, single dose, one day
Study: NCT02477891
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
Study: NCT04748419
Drug: Durvalumab 50 MG/ML
Normalized name: durvalumab 50 MG/ML
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
Study: NCT06155578
Drug: Topical 25% sodium metabisulfite (SM) in pediatric cold cream
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
Study: NCT06319768
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
Study: NCT06319768
Drug: platelet rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
Study: NCT06319768
Drug: combined pentoxifylline and platelet rich plasma
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
Study: NCT05763953
Drug: Etripamil NS
Normalized name: NS-2359
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A.
Study: NCT05453916
Drug: Nitazoxanide 500Mg Oral Tablet
Normalized name: Nitazoxanide 500mg Oral tablet
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
Study: NCT05453916
Drug: Rifaximin 550Mg Tab
Normalized name: RIFAXIMIN 550MG TAB
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
Study: NCT05429593
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet given orally
Study: NCT05429593
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet given orally
Study: NCT05429593
Drug: Semaglutide/dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet given orally
Study: NCT06348264
Drug: Rezvilutamide
Normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
Study: NCT06348264
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
Study: NCT03529448
Drug: Temozolomide Oral Product
Normalized name: temozolomide Oral Product
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.
Study: NCT05246072
Drug: Ivermectin + colchicine
Normalized name: Colchicine
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
Study: NCT05246072
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
Study: NCT06024915
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
Study: NCT06024915
Drug: Rifampicin Capsule
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin is a strong inducer of CYP3A.
Study: NCT06099951
Drug: Serplulimab + FOLFOXIRI
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
Study: NCT05221138
Drug: VV116
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: VV116 oral tablets, 400mg
Study: NCT04428008
Drug: Thymalfasin
Normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic 28 amino acid peptide
Study: NCT06146192
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colchicine 1-2 mg/day
Study: NCT06468670
Drug: sintilimab，programmed death 1 monoclonal antibody
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)
Study: NCT05799469
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC
Study: NCT05799469
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05730114
Drug: Antiplatelet Drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-P2Y12 oral agent administered during primary percutaneous coronary intervention.
Study: NCT04665609
Drug: Anlotinib and TQB2450 solution
Normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
Study: NCT05525247
Drug: SLC-3010
Normalized name: SLC-391
DrugBank: SLC-391 (DB18814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
Study: NCT04629443
Drug: S 64315 (also referred as MIK665) and azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days.
Study: NCT06008223
Drug: vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
Study: NCT06008223
Drug: 0.9% sodium chloride solution
Normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
Study: NCT05034536
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT05034536
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT05034536
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05034536
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT05616598
Drug: Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
Normalized name: Simeprevir
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
Study: NCT04669145
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
Study: NCT05573581
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
Study: NCT06487143
Drug: Triptorelin pamoate（15mg）
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
Study: NCT06487143
Drug: Triptorelin acetate （3.75mg）
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
Study: NCT01233570
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
Study: NCT04965116
Drug: Progestin Only Contraceptive Pills
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pill (placebo or active tablet)
Study: NCT05504213
Drug: HS-10352 combined with fulvestrant (Stage 1)
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study: NCT05504213
Drug: HS-10352 combined with fulvestrant (Stage 2)
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study: NCT06362343
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban
Study: NCT04310943
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab, 200mg, Q3W ,use until disease progression
Study: NCT05539521
Drug: Remimazolam Besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sedation drugs
Study: NCT05539521
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol
Study: NCT04785326
Drug: Stelara
Normalized name: Stelara
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45mg or 90mg dose subcutaneous administration